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ABSTRACT 
Objectives. Our objectives were to investigate the possible effects temperature and light 
have on the stability of dopamine and dobutamine continuous infusions over 24 hours when 
prepared in varying dilution vehicles. 
Methods Syringe-driver infusion apparatuses were set up of either dopamine or dobutamine, 
diluted with either 0.9% sodium chloride or 5% glucose, delivering 3mcg/kg/min and 
5mcg/kg/min respectively via 206 cm extension sets. All infusions were prepared for a neonate 
weight of 1 kg. Infusions were run over 24 hours, where approximately half the tubing was 
within an incubator set at 35ᵒC. Cyclic voltammetry was utilised to monitor the initial 
concentration of the inotrope and that after 24 hours within the syringe and end of the 
extension set.  
Results. The variation in the concentration of dopamine and dobutamine in the vials was 3.58 
% and 1.22 % respectively (n=6). This variation in the concentration increased to 10.88 % for 
dopamine and 5.76 % for dobutamine in preparation of the syringe. A significant reduction in 
the concentration of dopamine was observed at the end of the extension set after 24 hours 
when prepared in 0.9 % NaCl when compared to dopamine prepared in 5 % glucose (p<0.001, 
n=6-7) or dobutamine prepared in 0.9 % NaCl (p<0.001, n=6-7). No differences in the 
concentration of dopamine in 0.9 % NaCl were observed after 24 hours in light-exposed and 
light-protected extension sets (n=6-7). 
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Conclusions. Dobutamine is more stable in dilution vehicles when compared to dopamine 
and inotropes are more stable in 5 % glucose dilution vehicle when compared to 0.9 % NaCl. 
Such findings will provide guidance on the choice of inotropes. 
 
Key points 
• Inotropes such as dopamine and dobutamine are commonly utilised to treat neonatal 
hypotension and are administered as a continuous infusion over 24 hours  
• Under experimental conditions that mimicked the local neonatal unit environment, 
dopamine prepared in 0.9 % sodium chloride was significantly less stable than that 
prepared in 5 % glucose over 24 hours. Dopamine was also significantly less stable 
than dobutamine over 24-hours when prepared in 0.9 % sodium chloride. 
• Clinical staff might want to consider the results of our study, as our findings indicate 
that the stability of inotropes vary specifically in the dilution vehicle, of which 5% 
glucose is the preferred dilution vehicle.  
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INTRODUCTION 
Previous literature has quoted that hypotension develops between 20-50 % of all neonates 
admitted to the neonatal intensive care units (NICU) and is caused by conditions including 
patent ductus arteriosus or sepsis [1, 2]. Hypotension leads to inadequate organ perfusion 
and is thought to cause detrimental effects such as poor long-term neurodevelopment and 
associated increases in mortality [1-3]. Preterm neonates suffering from hypotension are 
particularly vulnerable to brain injury given the delicate sensitivity of developing cranial tissue 
to perfusion inadequacies [4]. Therefore, it is crucial that these patients are treated effectively 
to minimise the debilitating consequences.  
Inotropes, drugs that raise mean arterial pressures (MAP) by either improving myocardial 
contractility or increasing systemic vascular resistance, are commonly used to treat neonatal 
hypotension [2-6]. The most commonly used inotropes to treat neonatal hypotension are 
dopamine and dobutamine [2, 3, 7], which are administered intravenously (IV) as a continuous 
infusion by syringe drivers, and are changed every 24 hours. Within our local tertiary neonatal 
unit, it has been noted anecdotally that during changes between infusions, rapid swings in MAP 
were observed. This could potentially lead to a reduction in blood flow to the germinal matrix 
in the lateral ventricles of the brain which can cause ischaemia. Consequently re-perfusion of 
this region, as a result of a sudden rise in MAP can result in rupturing of these ischaemic blood 
vessels causing intraventricular haemorrhage, which is associated with poor 
neurodevelopment [8-10].  
Various explanation can be attributed to the rapid changes in MAP observed between 
infusions. These could be due variations in the preparation of inotropes as a dilution is 
required, dead space in infusion lines or the influence of multiple drugs entering through the 
same line causing a reduction in observed inotrope delivery. However, such changes are 
observed in patients with single or multiple inotropes on a regular basis, suggestive the 
underlying cause may be associated with the availability of the inotrope for therapeutic effect 
during the infusion rather than mode of delivery. One potential explanation of this observation 
is due to the stability of the drug. There are a limited number of studies conducted on the 
stability of dopamine and dobutamine which have found that light and temperature appear to 
be dominating factors for influencing stability [11-16]. However, most these studies have not 
been conducted on clinical doses and in environments that match ward settings. 
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The aim of this study was to investigate how environmental conditions (light and temperature) 
and vehicle (0.9% sodium chloride and 5% glucose) influence the stability of dopamine and 
dobutamine in a clinical laboratory model that is designed to mimic neonatal ward conditions.  
 
METHODS 
Preparation of the inotrope infusion solutions 
Vials of 40 mg/ml dopamine hydrochloride (Mercury Pharmaceuticals, Dublin, Ireland) or 12.5 
mg/ml dobutamine hydrochloride (Wockhardt, Wrexham, UK) were prepared in either 0.9% 
sodium chloride (NaCl) or 5% glucose to a concentration of 0.6 mg/mL. Dilutions of the vials 
were carried out using 1ml syringes as conducted on NICU. Within the NICU the weight of 
neonates varies, however we assumed a baby with a body weight of 1kg for the preparation 
of inotrope infusions. Infusion solutions were delivered at 3mcg/kg/min for dopamine and 
5mcg/kg/min for dobutamine, as recommended by the British National Formulary for Children 
(BNFC) as a starting dose prescribed for a 1kg neonate [17].  
 
Evaluating the stability of an inotrope infusion in a laboratory clinical model 
A small aliquot of the infusion solution was obtained to calculate the initial concentration of 
either dopamine or dobutamine. To simulate ward conditions, 50 ml syringes (Terumo, 
Lagana, Philippines) containing either 0.6 mg/mL dopamine or dobutamine were driven by a 
NIKI T34 syringe pump (Caesarea Medical Electronics, Lichtenstein, Germany), and set to run 
continuously for 24 hours at the flow rate determined by the BNFC. The syringe (placed in 
room temperature, 21 °C) was connected to a 206cm extension set (Alaris, Carefusion UK 
Ltd, Basingstoke, UK) which terminated to a 10cm bifurcated minibore extension set (Codan, 
Santa Ana, CA, USA) and a 21G needle. The needle pierced through parafilm which acted as 
a lid for the 15mL conical centrifuge tube (Thermo Fisher Scientific, Walthan, MA, UK) that 
was used to collect the infusion solution over the 24-hour period. Approximately half of the 
tubing and collecting tube were placed in a compact incubator (Thermo Fisher Scientific, 
Walthan, MA, UK) set at 35ᵒC (Figure 1). This is the maximum neonatal incubator 
temperature according to the Temperature Protocol routinely used in the local neonatal unit. 
Following 24 hours, a second aliquot was obtained from the remaining solution within the 
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syringe (Figure 1B, location A) and from the 15mL conical centrifuge tube (Figure 1C, location 
B).  
Aliquot samples were analysed for their concentration using cyclic voltammetry. To eliminate 
any temperature variation affecting cyclic voltammetry responses, a one in ten dilution was 
utilised for the analysis of each sample. The Electrochemical Analyser (CH Instruments) 
employed a 3-electrode system, where a 3 mm glassy carbon electrode served as the working 
electrode, a Ag|AgCl electrode served as the reference electrode and a platinum wire was 
utilised as a counter electrode. A scan rate of 50 mV/s was utilised for each of the cyclic 
voltammetry studies. 
 
Data analysis 
From each cyclic voltammogram, the oxidation peak current was recorded from the initial 
sample (measured 30 minutes following preparation) and those collected at location A and B 
after 24 hours. The current was converted to concentration of dopamine and dobutamine 
using calibration responses obtained using standards at concentrations reflective of those 
observed clinically. This data was statistically analysed using one-way paired ANOVA with 
post hoc Tukey tests.  
To compare between the inotropes and vehicle solutions they were prepared in, data was 
shown as the percent loss in the concentration of dopamine or dobutamine at location A and 
B after 24 hours, when compared to the initial response. This data was statistically analysed 
using two-way paired ANOVA with post hoc Sidak test.  
Data from each trial was presented as a data point in a before-after plot to observe the trend 
between the varying measures. Based on British Pharmacopeia guidelines for medicines 
production [18], any product > ±7.5% would be classed as unsuitable and therefore this was 
highlighted on the graphs presented.  
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RESULTS 
Vial variations and errors in dilution 
There was a 3.58 % variation in the concentration present in dopamine vials, however this 
was significantly lower for the dobutamine vials (1.22%, n=6 vials). Following dilution of the 
dopamine using a 1ml syringe to prepare a 0.6 mg/ml solution, the variance in the 
concentration of dopamine and dobutamine increased to 10.88 % and 5.76 % respectively 
(n=6 syringe preparations).  
 
Alterations in the concentration of dopamine infusions over 24 hours 
No visual changes were observed in the syringes post-infusion. The oxidation peaks of 
dopamine (0.4 V in 0.9 % NaCl and 0.6 V in 5 % glucose) in both vehicles from location A and 
B post-infusion were consistently lower than the initial response (Figure 2A and 2B).  When 
dopamine was prepared in 0.9 % NaCl, a significant decrease in the concentration was 
observed at location A (p<0.05, Tukey test) and B (p<0.01, Tukey test) when compared to 
the initial response (n=7, Figure 2C). There was also a significant decrease in the 
concentration between location A and B when dopamine was prepared in 0.9 % NaCl (p<0.01, 
Tukey test, Figure 2C). A similar, but less dramatic trend was seen in the glucose vehicle, 
where the concentration of dopamine significantly decreased at location B when compared 
to the initial response (p<0.05, n=6, Figure 2D). All trials in both NaCl and glucose showed 
similar patterns, with the concentration declining from initial to location A and then B. 
 
Alterations in the concentration of dobutamine infusions over 24 hours 
No visual changes were observed in the syringes post-infusion. The oxidation peaks of 
dobutamine (0.4 V in 0.9 % NaCl and 0.6 V in 5 % glucose) in both vehicles were like those 
observed for dopamine. The amplitude of the peaks from location A and B post-infusion were 
consistently lower than the initial response (Figure 3A and 3B).  When dobutamine was 
prepared in 0.9 % NaCl, a significant decrease in the concentration was observed at location 
A (p<0.01, Tukey test) and B (p<0.01, Tukey test) when compared to the initial response 
(n=7, Figure 3C). A similar effect was observed when prepared in 5 % glucose, where the 
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concentration of dobutamine significantly decreased at location B when compared to the initial 
response (p<0.01, Tukey test, n=6, Figure 3D). There was also a significant reduction in 
dobutamine concentration between location A and B (p<0.01, n=6). In both NaCl and glucose, 
similar patterns where observed, with the concentration declining over 24 hours at both 
locations. 
 
Influence of the dilution vehicle on the stability of dopamine and dobutamine 
The percentage change in concentration from initial response for each trial illustrates the 
magnitude of decay at location A and B (Figure 4). In trials of both dopamine and dobutamine 
infusions, the majority showed a reduction in the response from location A to B, suggestive 
that temperature as well as light may have a role in the stability of the two inotropes.  
For dopamine infusions prepared in 0.9 % sodium chloride, there was a significant reduction 
in the response from location A to B (p<0.001, Sidak test, n=7, Figure 4A & C). When 
comparing the preparation of dopamine in 0.9 % NaCl and 5 % glucose, no differences in the 
concentration lost after 24 hours was observed at location A (n=6-7), however a significantly 
greater concentration loss was observed in location B when dopamine syringes were prepared 
in 0.9 % NaCl when compared to 5 % glucose (p<0.001, Sidak test, n=6-7, Figure 4A). 
For dobutamine infusions prepared in 5 % glucose, there was a significant reduction in the 
concentration from location A to B (p<0.01, n=6, Figure 4B & D). No significant differences 
were observed in the degree of dobutamine concentration lost at location A and B in either 
0.9 % NaCl or 5 % glucose syringes after 24 hours (Figure 4B). 
The majority of trials for dopamine in 5 % glucose, dobutamine in 0.9 % NaCl and dobutamine 
5 % glucose were within pharmaceutical acceptable tolerance (indicated by the grey dashed 
lines in Figure 4) in both location A and B. The majority of trails for dopamine in 0.9 % NaCl 
in both location A and B were outside pharmaceutical acceptable tolerance guidelines. 
 
Differences in the stability of the inotropes in varying dilution vehicles 
In syringes prepared in 0.9 % NaCl, there was no significant difference in the concentration 
loss observed in dopamine and dobutamine at location A over 24 hours (n=6-7, Figure 4C).  
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A significant decrease in dopamine prepared in 0.9 % NaCl was observed when compared to 
dobutamine prepared in 0.9 % NaCl at location B after 24 hours (p<0.01, Sidak test, n=6-7, 
Figure 4C). 
In 5 % glucose preparations, no significant differences in the concentration were observed 
when comparing dopamine to dobutamine in either location A and B over 24 hours (n=6-7, 
Figure 4D) 
 
Influence of light on stability of dopamine syringes prepared in 0.9 % NaCl 
Our finding clearly indicates that dopamine infusions prepared in 0.9 % NaCl is the least stable 
over 24 hours. Therefore, we wanted to understand if this was mainly due to heat or light. 
To study this, we prepared syringes in light (clear tubing) and light-protected (orange tubing) 
extension sets and syringes. Figure 5 shows that there was a significant reduction in the 
concentration of dopamine prepared in 0.9 % NaCl in the orange tubing from location A to 
B over 24 hours (p<0.05, Sidak Test, n=6, Figure 5). Overall there is no significant difference 
in the degree of concentration loss observed at location A and B over 24 hours in the clear 
and orange tubing (n=6-7, Figure 5).  
 
 
DISCUSSION 
Variability in the vials and during infusion preparation 
We observed greater variability in the concentration of dopamine present in-between vials 
when compared to dobutamine. This increased variation was significantly enhanced following 
preparation of the syringe for infusion in both inotropes. In the case of the dopamine infusion 
the resultant variation in the concentration is already significantly greater than the acceptable 
pharmaceutical tolerance limits.  
The variation in the dopamine vials is most likely due to the smaller dose/volume utilised in 
the vial preparation when compared to dobutamine, which introduces more error in 
preparing infusions and diluting. Measuring inotrope concentration at every step from vial to 
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infusion, highlights the degree of error that is introduced in each step prior to delivery of the 
drug. This ultimately leads to inconsistency in the resulting clinical dose delivered to a neonate. 
It is widely acknowledged that preparation of medication in clinical practice is liable to a degree 
of error which can result in ill-prepared doses. Therefore, much work has gone into 
developing strategies to standardising clinical preparation of medications[19, 20]. However, 
such preparation errors need to be taken into consideration when titrating doses in between 
infusion changes. 
 
Differences in the stability of inotropes following 24-hour infusion 
The results illustrated in Figures 2 and 3 are suggestive that both dopamine and dobutamine 
concentrations decrease over 24 hours at both the syringe (location A) and the end of the 
infusion line (location B). These decreases are also irrespective of the dilution vehicle they are 
prepared in. Concentration losses in both inotropes is not surprising as catecholamine’s are 
well known to undergo oxidation and show limited stability [21]. Such decreases in stability 
should be negligent to the addition of antioxidant preservatives, however our findings indicate 
that this is still not sufficient to present loss in the concentration of dopamine and dobutamine. 
Looking solely at the concentration observed at 24 hours at location A and B relative to the 
initial prepared syringe provides limited information on the true impact of might have clinically, 
as in most instances the loss is less than 0.1 mg/ml over 24 hours due to the robust nature of 
the measurement. To gain insight into if such changes vary, the percentage change in the 
concentration from initial was obtained so that the differences in the dilution vehicle and type 
of inotrope could be obtained.   
Figure 4 shows that dopamine is significantly more stable when prepared in 5 % glucose when 
compared to 0.9 % NaCl and that dobutamine is more stable that dopamine when both are 
prepared in 0.9 % NaCl. Overall this indicates that dobutamine is more stable than dopamine 
in our ward-stimulated conditions and inotropes are more stable in 5 % glucose than 0.9 % 
NaCl. Dobutamine’s enhanced stability under all investigated conditions may be due to its 
larger molecular weight and chemical structure, which can resist oxidation when compared 
to dopamine. More interesting within out study was the finding that inotropes are more stable 
in glucose than NaCl. This has not been shown before, however this may be due to the fact 
at previous studies have predominately all utilised glucose as the vehicle for the preparation 
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of the inotropes, or have only focused on one type of vehicle when investigating stability [15, 
16]. It is unknown on why preparation in glucose provides more stability to the inotrope 
infusion, however it may be associated with the higher solution viscosities and and/or varying 
pH and therefore restricting diffusion of the inotropes and preservatives during infusion.  
Within our clinical model, the ability to record concentrations of the inotropes at location A 
and B provides insight into the factors that result in a loss in the stability of the drugs. At 
location A, which represents the syringe, the temperature is not altered and therefore light 
plays the significant contribution to the loss in stability. However, at location B, where half of 
the extension set is placed within the incubator both light and temperature are responsible 
for the changes in inotrope concentrations. In all trails conducted, a decrease in the 
concentration was observed at location B when compared to A. In all trials, there is a loss in 
the concentration of the inotrope at location A after 24 hours. At location B, the loss in the 
concentration after 24 hours was approximately between 5-10 % from initial in all conditions 
(2.7 – 2.85 mcg/kg/min for dopamine and 4.5 - 4.75 mcg/kg/min for dobutamine) bar that of 
dopamine in 0.9 % NaCl, where losses were between 10-35% (1.95 – 2.7 mcg/kg/min).  
Our data indicate that light does influence the stability of the inotropes, but elevated 
temperature has a more enhanced effect on reducing the stability of the inotropes. Exposure 
to light is thought to be one of the dominating stability factors [14, 15, 22], however in our 
study differentiation in the stability of inotropes in varying dilution vehicles was not seen at 
location A after 24 hours. More importantly we did not observe any significant differences in 
the concentration of dopamine in 0.9 % NaCl at location A and B after 24 hours in clear and 
orange tubing (utilised to present light). Previous studies have also shown that in differing 
types of light, dopamine is stable in those all those conditions [23].  
This would indicate that temperature plays a pivotal role in altering the stability of the 
inotropes over a 24-hour infusion. Due to this it would be interesting to note whether 
neonates undergoing hypothermia therapy for hypoxic ischaemic encephalopathy would 
experience similar reductions or fluctuations in MAP towards the end of a 24-hour inotrope 
infusion as the evaluated temperature of the incubator would be negated. Other factors that 
could explain the potential loss in the concentration of dopamine and dobutamine may be due 
to oxygen levels causing oxidation of inotropes or due to the adsorption/leaching of the drug 
onto the syringe and extension set tubing.   
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Despite great efforts being made to simulate neonatal ward conditions as accurately as 
possible in a laboratory setting, there are a few experimental design limitations which can 
affect the interpretation of the data. These include the nature of the incubator utilised, which 
does not allow for maximal light, as utilised on the neonatal ward, therefore underestimating 
the degree of degradation. Secondly, the collection tube remained in the incubator for the 
duration of the 24 hours, therefore overestimating the degree of degradation. Overall these 
two limitations may compensate for one another; the observed tends in our data are more 
likely to reflect the stability of the inotropes, even if the precise levels observed may not be 
accurate.  
Another important consideration is that our study is a very simple clinical model that doesn’t 
fully mimic drug delivery of inotropes, as often they are co-administered with other 
compounds, formulations, or parenteral nutrition. The latter, which is more commonly 
utilised is of significance as these formulations often contain NaCl, which could potentially 
alter the stability of dopamine no matter which dilution vehicle the drug was prepared in. 
Another important factor to consider is that the data presented highlights that impact of 
changes in the accuracy of concentration due to environmental factors and medicine 
preparation. Such factors in combination can have significant reductions in the delivered dose 
compared to actual dose which may result in why most infusions are titrated during delivery. 
Significantly clinical consideration needs to be taken into the impact of these factors during 
delivery of inotropes, particularly during times of syringe changes.  
 
 
Conclusion 
Overall the stability study has shown that during a 24-hour continuous infusion, under 
conditions such as exposure to light and 35ᵒC temperature as experienced in NICU, 
dobutamine is a more stable inotrope than dopamine and 5% glucose is a more stable vehicle 
than 0.9% NaCl. These findings may indicate why particular fluctuations in the MAP are 
observed during changeover of infusions. Clinical staff might want to take the results of our 
study into account when prescribing inotropes in the future as 5% glucose might be the 
preferred dilution vehicle or dobutamine as the inotrope if 0.9 % NaCl dilution vehicle is 
needed.  
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FIGURE LEGENDS 
Figure 1. Experiment set up of the continuous infusion. (A) A photograph showing the 
experiment set-up during an infusion, where half of the extension set is placed inside the 
incubator at 35 °C. (B) A photograph of the syringe and syringe driver delivering the inotrope, 
which is location A. (C) Close up photograph of the equipment inside the incubator depicting 
the IV tubing and collecting tube. The sample monitored at source B represents the inotrope 
concentration at the point of venous catheter entry. 
 
Figure 2. Stability data for dopamine infusion. Cyclic voltammograms following initial 
measurements and after 24 hours in location A (syringe) and B (end of the extension set) in 
(A) 0.9% NaCl and (B) 5 % glucose. Overall data from multiple studies showing the 
concentration of dopamine following initial measurements and after 24 hours in location A 
and B in (C) 0.9% NaCl and (D) 5 % glucose. Data shown as individual trials through a before-
after plot, where n=6-7, *p<0.05 and **p<0.01 (Tukey test)  
 
Figure 3. Stability data for dobutamine infusion. Cyclic voltammograms following initial 
measurements and after 24 hours in location A (syringe) and B (end of the extension set) in 
(A) 0.9% NaCl and (B) 5 % glucose. Overall data from multiple studies showing the 
concentration of dobutamine following initial measurements and after 24 hours in location A 
and B in (C) 0.9% NaCl and (D) 5 % glucose. Data shown as individual trials through a before-
after plot, where n=6-7, *p<0.05 and **p<0.01 (Tukey test) 
 
Figure 4. Percentage change in the concentration of inotropes from initial when compared 
to location A and B after 24 hours. Trials are shown for dopamine (A) and dobutamine (B) in 
varying dilution vehicles. Trials are shown for inotropes prepared in with 0.9 % NaCl (C) or 
5 % glucose (D). The dashed lines indicate the acceptable pharmaceutical tolerance of ±7.5%. 
Note that location A indicates the syringe and location B indicates the collection tube at the 
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end of the extension set tubing. Data shown as individual trials through a before-after plot, 
where n=6-7, **p<0.01 and ***p<0.001 (Sidak test) 
 
Figure 5. Influence of light on the stability of dopamine infusion prepared in 0.9 % NaCl. The 
percent change in the concentration of dopamine from initial is shown in location A and B 
after 24-hours when using light-sensitive (clear tubing) and light-protective (orange tubing) 
infusion sets. The dashed lines indicate the pharmaceutical tolerance of ±7.5%. Note that 
location A indicates the syringe and location B indicates the collection tube at the end of the 
extension set tubing. Data shown as individual trials through a before-after plot, where n=6-
7, **p<0.01 and ***p<0.001 (Sidak test) 
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